Vaccination among HIV-infected, HIV-exposed uninfected and HIV-uninfected children: a systematic review and meta-analysis of evidence related to vaccine efficacy and effectiveness

References

• World Health Organization. Position papers - summary of WHO position papers-recommendations for routine immunization; 2018 [accessed 2018 Jun 20]. http://www.who.int/immunization/policy/Immunization_routine_table1.pdf?ua=1.
   Google Scholar
• Bloom DE, Fan VY, Sevilla JP. The broad socioeconomic benefits of vaccination. Sci Trans Med. 2018;10(441):eaaj2345. doi:10.1126/scitranslmed.aaj2345.
   PubMed Web of Science ®Google Scholar
• Ozawa S, Clark S, Portnoy A, Grewal S, Brenzel L, Walker DG. Return on investment from childhood immunization in low-and middle-income countries, 2011–20. Health Affairs. 2016;35::199–207. doi:10.1377/hlthaff.2015.1086.
   Web of Science ®Google Scholar
• World Health Organization. 2015 assessment report of the Global Vaccine Action Plan. Geneva: WHO; 2016.
   Google Scholar
• Heffernan RT, Barrett NL, Gallagher KM, Hadler JL, Harrison LH, Reingold AL, Khoshnood K, Holford TR, Schuchat A. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995–2000. J Infect Dis. 2005;191:2038–45. doi:10.1086/430356.
   PubMed Web of Science ®Google Scholar
• Ormsby CE, de la Rosa-Zamboni D, Vázquez-Pérez J, Ablanedo-Terrazas Y, Vega-Barrientos R, Gómez-Palacio M, Murakami-Ogasawara A, Ibarra-Ávalos JA, Romero-Rodríguez D, Ávila-Ríos S, et al. Severe 2009 pandemic influenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease. AIDS. 2011;25::435–9. doi:10.1097/QAD.0b013e328343443b.
   PubMed Web of Science ®Google Scholar
• National Department of Health. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. Pretoria: NDOH; 2015. p. 128.
   Google Scholar
• Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Inf Dis. 2014;58:e44–100.
   PubMed Web of Science ®Google Scholar
• Valour F, Cotte L, Voirin N, Godinot M, Ader F, Ferry T, Vanhems P, Chidiac C. Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A (H1N1) 2009 pandemic influenza in HIV-infected patients. Vaccine. 2014;32:4558–64. doi:10.1016/j.vaccine.2014.06.015.
   PubMed Web of Science ®Google Scholar
• Tejiokem MC, Gouandjika I, Béniguel L, Zanga M-CE, Tene G, Gody JC, Njamkepo E, Kfutwah A, Penda I, Bilong C, et al. HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the expanded program on immunization. PLoS ONE. 2007;2:e1260. doi:10.1371/journal.pone.0001260.
   PubMed Web of Science ®Google Scholar
• Clark TA. Changing pertussis epidemiology: everything old is new again. J Inf Dis. 2014;209:978–81. doi:10.1093/infdis/jiu001.
   PubMed Web of Science ®Google Scholar
• Machingaidze S, Wiysonge CS, Hussey GD. Strengthening the expanded programme on immunization in Africa: looking beyond 2015. PLoS Med. 2013;10::1–5. doi:10.1371/journal.pmed.1001405.
   Web of Science ®Google Scholar
• Mangtani P, Mulholland K, Madhi SA, Edmond K, O’Loughlin R, Hajjeh R. Haemophilus influenzae type b disease in HIV-infected children: A review of the disease epidemiology and effectiveness of Hib conjugate vaccines. Vaccine. 2010;28:1677–83. doi:10.1016/j.vaccine.2009.12.011.
   PubMed Web of Science ®Google Scholar
• Jallow S, Madhi SA, Madimabe R, Sipambo N, Violari A, Kala U, Petersen K, Naidoo S, Verwey C, Moore DP, et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions. Vaccine. 2017;35:4321–29. doi:10.1016/j.vaccine.2017.06.081.
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. New England J Med. 2003;349:1341–48. doi:10.1056/NEJMoa035060.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Laserson KF, Ojwando J, Nyambane G, Ssempijja V, Audi A, Nyakundi D, Oyieko J, Dallas MJ, Ciarlet M, et al. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya (Special Issue: rotavirus vaccines for children in Developing Countries.). Vaccine. 2012;64(4):407–15.
   Google Scholar
• Madhi SA, Adrian P, Kuwanda L, Jassat W, Jones S, Little T, Soininen A, Cutland C, Klugman KP. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine. 2007;25:2451–57. doi:10.1016/j.vaccine.2006.09.019.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Kuwanda L, Cutland C, Klugman KP. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Inf Dis. 2005;40:1511–18. doi:10.1086/429828.
   PubMed Web of Science ®Google Scholar
• Steele AD, Madhi SA, Louw CE, Bos P, Tumbo JM, Werner CM, Bicer C, De Vos B, Delem A, Han HH. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatr Inf Dis J. 2011;30:125–30. doi:10.1097/INF.0b013e3181f42db9.
   PubMed Web of Science ®Google Scholar
• Cohen C, Von Mollendorf C, De Gouveia L, Naidoo N, Meiring S, Quan V, Nokeri V, Fortuin-de Smit M, Malope-Kgokong B, Moore D, et al. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in south Africa: a matched case-control study. Clin Inf Dis. 2014;59:808–18. doi:10.1093/cid/ciu431.
   PubMed Web of Science ®Google Scholar
• Cohen C, von Mollendorf C, de Gouveia L, Lengana S, Meiring S, Quan V, Nguweneza A, Moore DP, Reubenson G, Moshe M, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study. Lancet Glob Health. 2017;5:e359–69. doi:10.1016/S2214-109X(17)30043-8.
   PubMed Web of Science ®Google Scholar
• Van-Dunem JCVD, Rodrigues LC, Alencar LCA, Militão-Albuquerque MDFP, Ximenes RADA. Effectiveness of the first dose of BCG against tuberculosis among HIV-infected, predominantly immunodeficient children. BioMed Res Int. 2015;2015:275029. doi:10.1155/2015/275029.
   PubMed Web of Science ®Google Scholar
• Groome MJ, Page N, Cortese MM, Moyes J, Zar HJ, Kapongo CN, Mulligan C, Diedericks R, Cohen C, Fleming JA, et al. Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: A case-control study. Lancet Inf Dis. 2014;14:1096–104. doi:10.1016/S1473-3099(14)70940-5.
   PubMed Web of Science ®Google Scholar
• Bhat GJ, Diwan VK, Chintu C, Kabika M, Masona J. HIV, BCG and TB in children: A case control study in Lusaka, Zambia. J Trop Pediatr. 1993;39(4):219–23. doi:10.1093/tropej/39.4.219.
   PubMed Web of Science ®Google Scholar
• Bar-Zeev N, Jere KC, Bennett A, Pollock L, Tate JE, Nakagomi O, Iturriza-Gomara M, Costello A, Mwansambo C, Parashar UD, et al. Population impact and effectiveness of monovalent rotavirus vaccination in Urban Malawian children 3 years after vaccine introduction: ecological and case-control analyses. Clin Inf Dis. 2016;62:S213–9. doi:10.1093/cid/civ1183.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Petersen K, Khoosal M, Huebner RE, Mbelle N, Mothupi R, Saloojee H, Crewe-Brown H, Klugman KP. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Inf Dis J. 2002;21:315–21. doi:10.1097/00006454-200204000-00011.
   PubMed Web of Science ®Google Scholar
• Beghin J-C, Ruelle J, Sokal E, Bachy A, Krishna M, Hall L, Goubau P, Van der Linden D. Effectiveness of the South African expanded program of immunization against hepatitis B in children infected with human immunodeficiency virus-1 living in a resource-limited setting of Kwazulu-Natal. J Med Virol. 2017;89:182–85. doi:10.1002/jmv.v89.1.
   PubMed Web of Science ®Google Scholar
• Simani OE, Leroux-Roels G, François G, Burnett RJ, Meheus A, Mphahlele MJ. Reduced detection and levels of protective antibodies to hepatitis B vaccine in under 2-year-old HIV positive South African children at a paediatric outpatient clinic. Vaccine. 2009;27:146–51. doi:10.1016/j.vaccine.2008.10.004.
   PubMed Web of Science ®Google Scholar
• Laserson KF, Nyakundi D, Feikin DR, Nyambane G, Cook E, Oyieko J, Ojwando J, Rivers SB, Ciarlet M, Neuzil KM, et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq®, in Kenya, including among HIV-infected and HIV-exposed infants. Vaccine. 2012;30:A61–70. doi:10.1016/j.vaccine.2011.09.026.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pneumococcal vaccines WHO position paper - 2012. Weekly Epidemiol Record [Internet]. 2012;21:421–28.
   Google Scholar
• Mutsaerts EAML, Nunes MC, van Rijswijk MN, Klipstein-Grobusch K, Grobbee DE, Madhi SA. Safety and immunogenicity of measles vaccination in HIV-infected and HIV-exposed uninfected children: a systematic review and meta-analysis. EClinMed. 2018;1:28–42.
   PubMedGoogle Scholar
• Scott P, Moss WJ, Gilani Z, Low N. Measles vaccination in HIV-infected children: systematic review and meta-analysis of safety and immunogenicity. J Inf Dis. 2011;204:S164–78. doi:10.1093/infdis/jir071.
   PubMed Web of Science ®Google Scholar
• Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Human Vacc Immunother. 2012;8::161–73. doi:10.4161/hv.18432.
   PubMed Web of Science ®Google Scholar
• Joint United Nations Programme on HIV/AIDS. UNAIDS data 2017. Geneva: UNAIDS; 2017.
   Google Scholar
• Hesseling AC, Cotton MF, Fordham von Reyn C, Graham SM, Gie RP, Hussey GD. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants: submitted on behalf of the BCG Working Group, Child Lung Health Section, International Union Against Tuberculosis and Lung Disease, 38th Union World Conference on Lung Health, Cape Town, 8–12 November 2007 [Official statement]. Int J Tuberc Lung Dis. 2008;12:1376–79.
   PubMed Web of Science ®Google Scholar
• UNAIDS. Aidsinfo [accessed 2019 Jan 25]. http://aidsinfo.unaids.org/.
   Google Scholar
• Abajobir AA, Abbafati C, Abbas KM, Abbas KM, Abd-Allah F, Abera SF, Aboyans V, Adetokunboh O, Afshin A, Agrawal A, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017;390:1151–210. doi:10.1016/S0140-6736(17)32152-9.
   PubMed Web of Science ®Google Scholar
• Dlamini SK, Madhi SA, Muloiwa R, Von Gottberg A, Moosa M-YS, Meiring ST, Wiysonge CS, Hefer E, Mulaudzi MB, Nuttall J, et al. Guidelines for the vaccination of HIV-infected adolescents and adults in South Africa. S Afr J HIV Med. 2018;19(1):1–8. doi:10.4102/sajhivmed.v19i1.839.
   Google Scholar
• World Health Organization. BCG vaccines: wHOposition paper-February 2018. Weekly Epidemiol Record. 2018;8::73–96.
   Google Scholar
• Centers for Disease Control and Prevention. Immunization schedule for infants and children (Birth through 6 Years) [accessed 2019 Jan 25]. https://www.cdc.gov/vaccines/schedules/easy-to-read/child.html.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;151:264–69.
   Google Scholar
• Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. [updated Mar 2011]. Chichester, UK: Cochrane Collaboration; 2011.
   Google Scholar
• Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials. 1996;17:1–2.
   PubMedGoogle Scholar
• Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
   Google Scholar
• Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, Falck-Ytter Y, et al. GRADE guidelines: 4. Rating the quality of evidence - Study limitations (risk of bias). J Clin Epidemiol. 2011;64:407–15. doi:10.1016/j.jclinepi.2010.07.017.
   PubMed Web of Science ®Google Scholar